middle.news
Chimeric Therapeutics Advances CHM CDH17 CAR-T Trial to Higher Dose with Promising Safety
2:00am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Advances CHM CDH17 CAR-T Trial to Higher Dose with Promising Safety
2:00am on Monday 2nd of June, 2025 AEST
Key Points
Dose Level 2 escalated to 150 million CAR-T cells following safe completion of Dose Level 1
No dose-limiting toxicities or off-target effects observed in initial patients
Early clinical activity includes stable disease in colorectal and neuroendocrine tumor patients
Seven successful manufacturing runs completed to date
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CHM
OPEN ARTICLE